Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01649661 · ClinicalTrials.gov registry record
MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 437
- Enrollment target
NCT01649661: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01649661 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 437 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01649661 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 437 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about how a woman's health history influences what a normal breast looks like on an MRI. The investigators also want to learn about how the amount of different natural hormones a woman has affects how the breast looks on an MRI. The investigator's hope is that this will help to find women at a high-risk of breast cancer.
Interventions
- BEHAVIORAL questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2012-07 |
| Est. Completion | 2023-01-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01649661
The ClinicalTrials.gov registry entry for NCT01649661 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 437 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which questionnaire is the first listed.
NCT01649661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01649661 about?
NCT01649661 is a clinical study titled "MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk". The purpose of this study is to learn about how a woman's health history influences what a normal breast looks like on an MRI. The investigators also want to learn about how the amount of different natural hormones a woman has affects how the breast looks on an MRI. The investigator's hope is that t...
What is the current status of trial NCT01649661?
This trial is currently completed. The enrollment target is 437 participants. The study started on 2012-07. Estimated completion is 2023-01-25.
What interventions are being tested in trial NCT01649661?
The interventions under investigation include: questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT01649661?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.